Category Archives: People

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978  Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen Data from the first […]

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well […]

New Again Houses® Welcomes New Cash Home Buyer in Sarasota, FL

Multi-Faceted Real Estate Business Celebrates Continued Success with the Opening of Its 66th Cash Home Buying Franchise in Sarasota, FL SARASOTA, Fla., June 05, 2026 (GLOBE NEWSWIRE) — New Again Houses®, a company that transforms old houses into fantastic modern homes, is thrilled to announce the opening of their 66th location in Sarasota, FL! The […]

New Again Houses® Welcomes New Cash Home Buyer in Pinellas County, FL

Multi-Faceted Real Estate Business Celebrates Continued Success with the Opening of Its 65th Cash Home Buying Franchise in Pinellas County, FL ST. PETERSBURG, Fla., June 05, 2026 (GLOBE NEWSWIRE) — New Again Houses®, a company that transforms old houses into fantastic modern homes, is thrilled to announce the opening of their 65th location in Pinellas […]

UREVO Debuts Smart Wellness Pop-Up in SoHo

Three-day public experience during New York Tech Week showcases the future of active work and recovery NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) — New York never stops. Yet despite the city’s constant motion, many professionals spend much of their workday sitting still. To challenge that reality, UREVO will debut a three-day Smart Wellness Pop-Up […]

TerraSpark Energy Campus Wins $18.5M DOE Grant for West Virginia Power and Carbon Capture Project

Project will deliver 1.6 GW of reliable, low-emission, affordable baseload power with next-generation carbon capture technology MOUNT STORM, W.Va., June 05, 2026 (GLOBE NEWSWIRE) — TerraSpark today announced that the U.S. Department of Energy (DOE) has selected the TerraSpark Energy Campus to receive up to $18.5 million in federal funding to finance development of an […]

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction Exploratory analysis of inhaled insulin used with AID systems provides insight on the […]

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up […]

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes […]

Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism

STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) — Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. […]